Recent developments in the field of obesity treatment have brought a novel drug known as ALLUVI Retatrutide. This compound is a {highlyspecific GLP-1 receptor agonist, engineered to mimic the effects of natural glucagon-like peptide-1. Retatrutide has shown remarkable results in clinical trials, exhibiting significant reductions in body weight and